Autoimmune disease
MONDO:0007179A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to their own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).
Also known as: autoimmune disease, autoimmune disease or disorder, autoimmune disorder, disease, autoimmune, autoimmune hypersensitivity disease, hypersensitivity reaction type II disease
4033 clinical trials for this condition and its sub-types, 313 tagged with Autoimmune disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Autoimmune disease
-
Autoimmune disorder of the nervous system 47 trials · 1,060 incl. sub-types
4 sub-types
- Autoimmune disorder of central nervous system 2 trials · 874 incl. sub-types Sub-types →
- Autoimmune disorder of peripheral nervous system 0 trials · 194 incl. sub-types Sub-types →
- Pediatric acute-onset neuropsychiatric syndrome 8 trials · 10 incl. sub-types Sub-types →
- Autoimmune retinopathy 0 trials
-
Autoimmune disorder of gastrointestinal tract 0 trials · 936 incl. sub-types
7 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Celiac disease 79 trials Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune enteropathy 2 trials · 11 incl. sub-types Sub-types →
- Autoimmune gastritis 3 trials
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related sclerosing cholangitis 0 trials
-
Autoimmune disorder of endocrine system 1 trial · 925 incl. sub-types
13 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Autoimmune thyroid disease 8 trials · 62 incl. sub-types Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune polyendocrinopathy 3 trials · 11 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- Autoimmune hypoparathyroidism 0 trials · 8 incl. sub-types Sub-types →
- Autoimmune pancreatitis 3 trials Sub-types →
- Autoimmune primary ovarian failure 1 trial
- IgG4-related sclerosing cholangitis 0 trials
- Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome 0 trials
- Autoimmune oophoritis 0 trials
- Insulin autoimmune syndrome 0 trials
- Primary hypophysitis 0 trials Sub-types →
-
CNS demyelinating autoimmune disease 5 trials · 853 incl. sub-types
1 sub-type
- Multiple sclerosis 765 trials · 852 incl. sub-types Sub-types →
-
Autoimmune disorder of musculoskeletal system 0 trials · 795 incl. sub-types
3 sub-types
- Rheumatoid arthritis 576 trials · 795 incl. sub-types Sub-types →
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Neonatal dermatomyositis 0 trials
-
Lupus erythematosus 39 trials · 548 incl. sub-types
3 sub-types
- Systemic lupus erythematosus 516 trials · 522 incl. sub-types Sub-types →
- Cutaneous lupus erythematosus 38 trials · 46 incl. sub-types Sub-types →
- Drug-induced lupus erythematosus 1 trial
-
Scleroderma 47 trials · 305 incl. sub-types
3 sub-types
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Localized scleroderma 14 trials · 15 incl. sub-types Sub-types →
- Neonatal scleroderma 0 trials
-
Autoimmune disorder of exocrine system 0 trials · 196 incl. sub-types
3 sub-types
- Sjogren syndrome 166 trials
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Benign lymphoepithelial lesion of salivary gland 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Evans syndrome 19 trials
-
Vitiligo 100 trials
3 sub-types
- Generalized vitiligo 16 trials
- Alopecia universalis onychodystrophy vitiligo 0 trials
- Trichrome vitiligo 0 trials
-
Antiphospholipid syndrome 58 trials · 59 incl. sub-types
4 sub-types
- Primary antiphospholipid syndrome 4 trials
- Catastrophic antiphospholipid syndrome 1 trial
- Familial antiphospholipid syndrome 0 trials
- Secondary antiphospholipid syndrome 0 trials Sub-types →
-
Autoimmune bullous skin disease 7 trials · 55 incl. sub-types
11 sub-types
- Pemphigus 20 trials · 27 incl. sub-types Sub-types →
- Bullous pemphigoid 18 trials
- Mucous membrane pemphigoid 5 trials · 9 incl. sub-types Sub-types →
- Acquired epidermolysis bullosa 3 trials
- Dermatitis herpetiformis 1 trial Sub-types →
- Pemphigoid 1 trial
- IgA pemphigus 0 trials
- Anti-p200 pemphigoid 0 trials
- Linear IgA Dermatosis 0 trials
- Paraneoplastic pemphigus 0 trials
- Subcorneal pustular dermatosis 0 trials
-
Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types
14 sub-types
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related kidney disease 1 trial
- IgG4-related retroperitoneal fibrosis 1 trial Sub-types →
- IgG4-related aortitis 0 trials
- IgG4-related mediastinitis 0 trials
- IgG4-related mesenteritis 0 trials
- IgG4-related ophthalmic disorder 0 trials Sub-types →
- IgG4-related pachymeningitis 0 trials
- IgG4-related sclerosing cholangitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- IgG4-related thyroid disease 0 trials
- Cutaneous pseudolymphoma 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
- Primary cutaneous plasmacytosis 0 trials
-
Rheumatic fever 16 trials
-
Overlapping connective tissue disease 2 trials · 15 incl. sub-types
2 sub-types
- Mixed connective tissue disease 15 trials
- MASS syndrome 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
Type III hypersensitivity disease 3 trials · 6 incl. sub-types
2 sub-types
- Serum sickness 3 trials
- Arthus reaction 0 trials
-
Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types
7 sub-types
- Autoimmune inner ear disease 2 trials
- Autoimmune uveitis 2 trials
- Cogan syndrome 0 trials
- IgG4-related dacryoadenitis and sialadenitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- Autoimmune retinopathy 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
-
Cryoglobulinemia 3 trials
1 sub-type
- Cryofibrinogenemia 0 trials Sub-types →
-
Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types
6 sub-types
- Chilblain lupus 1 trial · 3 incl. sub-types Sub-types →
- Libman-Sacks endocarditis 0 trials
- Autoimmune atherosclerosis 0 trials
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Autoimmune vasculitis 0 trials Sub-types →
- Rheumatic pulmonary valve disease 0 trials
-
Susac syndrome 2 trials
-
Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types
-
Phacolytic glaucoma 1 trial
-
Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types
6 sub-types
- Neonatal lupus erythematosus 1 trial
- Neonatal antiphospholipid syndrome 0 trials
- Neonatal autoimmune hemolytic anemia 0 trials
- Neonatal dermatomyositis 0 trials
- Neonatal scleroderma 0 trials
- Transient neonatal myasthenia gravis 0 trials
-
Jaccoud syndrome 0 trials
-
Kimura disease 0 trials
-
Reynolds syndrome 0 trials
-
Autoimmune glomerulonephritis 0 trials
-
Autoimmune urticaria 0 trials
-
Euthyroid Graves orbitopathy 0 trials
-
Tempi syndrome 0 trials
Most studied deeper sub-types
-
New Sjögren's drug ASP5502 enters first human tests
Disease control Stopped earlyThis early-stage study tested a new oral drug, ASP5502, for primary Sjögren's syndrome, an autoimmune condition causing dry eyes and mouth. It involved 116 healthy adults and patients to check safety and how the body processes the drug. The study was terminated, but results may g…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control Stopped earlyThis phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental CAR-T therapy takes aim at Hard-to-Treat scleroderma
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own modified immune cells to target and destroy certain B cells tha…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could CAR-T cells tame tough lupus kidney disease?
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental drug aims to save Insulin-Making cells in newly diagnosed type 1 diabetes
Disease control Stopped earlyThis Phase 2 trial tested an oral drug called ladarixin in 141 people aged 14-45 recently diagnosed with type 1 diabetes. The goal was to see if ladarixin could preserve the body's ability to produce insulin by protecting beta cells. The study was terminated early, so while it ma…
Phase 2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control Stopped earlyThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New shot aims to keep insulin flowing in type 1 diabetes
Disease control Stopped earlyThis study tests a drug called Diamyd in people aged 12 to 29 who were recently diagnosed with type 1 diabetes and have a specific genetic type (HLA DR3-DQ2). The goal is to see if Diamyd can help the body keep making its own insulin, which could improve blood sugar control and r…
Phase 3 • Sponsor: Diamyd Medical AB • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Lupus skin drug trial halted early – only 8 volunteers joined
Disease control Stopped earlyThis study tested an experimental drug called PF-06823859 for adults with lupus that affects the skin. The goal was to see if the drug could reduce skin inflammation and improve symptoms. The trial was stopped early and only enrolled 8 people instead of the planned 48, so results…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for nerve disease: batoclimab safety trial expands
Disease control Stopped earlyThis study checks the long-term safety of a drug called batoclimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 108 people who finished an earlier batoclimab study will get weekly injections fo…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new antibody calm the immune attack in CIDP?
Disease control Stopped earlyThis trial is testing whether an experimental drug called batoclimab can help adults with active chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system damages nerves, causing weakness and disability. Participants receive either batoclimab o…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new biologic tame lupus flares?
Disease control Stopped earlyThis trial is testing whether an experimental biologic called MK-6194 can reduce disease activity in adults with systemic lupus erythematosus (SLE), an autoimmune condition that causes inflammation and organ damage. Participants receive either MK-6194 or a placebo as an injection…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new hip implant stand the test of time?
Disease control Stopped earlyThis study follows about 300 people who receive a hip replacement using the GTS cementless stem, a type of implant that anchors to bone without cement. The goal is to see how well the implant performs over up to 10 years, measuring pain, function, and joint stability. Participant…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental MS drug tested in kids, but study halted early
Disease control Stopped earlyThis study tested the drug alemtuzumab in children aged 10 to 18 with relapsing-remitting multiple sclerosis (MS) whose disease was still active despite other treatments. The goal was to see if the drug could reduce new brain lesions and improve quality of life. However, the tria…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a new drug help preserve insulin production in type 1 diabetes?
Disease control Stopped earlyThis early-stage trial tested four different doses of siplizumab in 8 people aged 8–45 who were diagnosed with type 1 diabetes within the past 18 months. The goal was to find a safe dose that changes certain immune cell patterns linked to better insulin production. Participants r…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Rheumatoid arthritis combo drug trial stalls after just 2 patients
Disease control Stopped earlyThis early-stage trial tested whether adding an experimental drug called VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis. Only 2 participants were enrolled before the study was terminated, so no meaningful conclusions ca…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New arthritis drug trial for kids: could filgotinib help?
Disease control Stopped earlyThis study is testing the drug filgotinib in children aged 8 to 17 with juvenile idiopathic arthritis (JIA), a condition causing joint pain and swelling. The goal is to see how the drug moves through the body and if it is safe. Ten children with moderate to severe JIA that is not…
Phase 1 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for vitiligo: experimental drug aims to restore skin color
Disease control Stopped earlyThis study tested an experimental drug called MK-6194 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could safely reduce the amount of vitiligo on the face compared to a placebo. The trial was stopped earl…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Iron infusions may boost gut healing in celiac disease
Disease control Stopped earlyThis trial investigates whether adding intravenous iron to standard oral iron supplements can help heal intestinal damage in people with celiac disease who have iron deficiency and gut atrophy. Participants receive either intravenous iron infusions plus oral iron, or oral iron al…
Phase 4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Ankle implant tracked for Long-Term success in arthritis patients
Disease control Stopped earlyThis study followed 65 adults with ankle arthritis (from wear-and-tear, injury, or conditions like rheumatoid arthritis) who received the Cadence Total Ankle System implant. Researchers tracked how long the implant lasted without needing removal or revision, checking at 2, 5, and…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New RA drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called LY3541860 in 35 adults with moderate-to-severe rheumatoid arthritis who had not improved enough on other treatments. The goal was to see if the drug could reduce joint swelling and pain. However, the trial was terminated early, so the…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control Stopped earlyThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smartphone system aims to automate insulin delivery for type 1 diabetes
Disease control Stopped earlyThis study tests an automated insulin delivery system for adults with type 1 diabetes. The system uses a smartphone connected to a continuous glucose monitor and insulin pump to help keep blood sugar levels in a healthy range, especially overnight. Ten participants compare the au…
Sponsor: Sue Brown • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Shoulder implant under review: will it last 10 years?
Disease control Stopped earlyThis study looked at a shoulder implant used to treat pain and joint problems from conditions like arthritis, fractures, and rotator cuff tears. It involved 67 adults who received the implant and tracked how long it lasted and any side effects over 10 years. The goal was to confi…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill for rheumatoid arthritis shows promise in early trial
Disease control Stopped earlyThis phase 2 study tested an experimental oral drug called BGB-45035 in 49 adults with moderate to severe rheumatoid arthritis who had not responded well to standard treatments. Participants received either the drug or a placebo to see if it could reduce joint pain and swelling. …
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Rheumatoid arthritis drug study halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called GS-0272 in adults with rheumatoid arthritis to see if it is safe and how the body processes it. The trial was stopped early, so results are limited. About 55 people were planned to take part, receiving either the drug or a placebo.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Botulinum injection trial for arm spasticity halted early
Disease control Stopped earlyThis study tested whether injections of MYOBLOC (botulinum toxin type B) can safely reduce muscle tightness in the arm and hand of adults with spasticity caused by stroke, brain injury, multiple sclerosis, or other conditions. The trial planned to enroll about 300 participants bu…
Phase 2/3 • Sponsor: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental immune therapy for stubborn anemia shows early promise but trial stalls
Disease control Stopped earlyThis early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four …
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental diabetes drug trial halted early
Disease control Stopped earlyThis study tested an experimental drug called TOL-3021 in people with type 1 diabetes to see if it could help preserve the body's ability to produce insulin. The trial enrolled 78 participants aged 12 to 41 who had been diagnosed within the last 5 years. The study was terminated …
Phase 2 • Sponsor: Tolerion, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Anti-Inflammatory drug studied for PANDAS-Related OCD in kids
Disease control Stopped earlyThis study tested the anti-inflammatory drug naproxen sodium for treating obsessive-compulsive symptoms in children aged 6-15 with PANDAS, a condition linked to strep infections. The trial was double-blind and placebo-controlled, but it was terminated early after enrolling only 2…
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Discoid lupus drug trial halted midway
Disease control Stopped earlyThis study tested an experimental drug called daxdilimab in 72 adults with moderate-to-severe discoid lupus erythematosus, a skin condition that causes scarring and hair loss. The goal was to see if the drug could reduce disease activity compared to a placebo. However, the trial …
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cream aims to stop vitiligo relapse after repigmentation
Disease control Stopped earlyThis trial tested a cosmetic cream called RV5098A to see if it could help adults with vitiligo keep their facial pigmentation after successful repigmentation treatment. Vitiligo causes white patches on the skin, and even after treatment, about 40% of people lose color again withi…
Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
CRISPR's diabetes cell therapy trial ends early
Disease control Stopped earlyThis early-stage study tested a new treatment called VCTX211 for people with type 1 diabetes. The goal was to see if implanting these special cells could help the body make insulin and reduce the need for insulin shots. Only 5 people took part, and the study was stopped early. Th…
Phase 1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising diabetes delay study halted due to lack of participants
Disease control Stopped earlyThis study tested a low dose of a drug called ATG to see if it could delay or prevent type 1 diabetes in people at high risk. Only 2 people enrolled, so the study was stopped early. The goal was to measure how long it took for participants to develop full-blown diabetes.
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Sjögren's drug trial halted: what happened?
Disease control Stopped earlyThis study tested an experimental drug called HZN-1116 in 209 people with Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The goal was to see if the drug could reduce disease activity and symptoms. The trial was terminated early, so results may not be availa…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Old allergy drug may help repair nerves in MS patients
Disease control Stopped earlyThis study tested whether clemastine fumarate, an allergy medication, could improve eye movement problems in people with multiple sclerosis (MS). The trial planned to enroll 80 MS patients with a specific eye condition called internuclear ophthalmoparesis, but was terminated earl…
Phase 3 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Batoclimab shows promise for thyroid eye disease in extension study
Disease control Stopped earlyThis study is for people who finished earlier trials of batoclimab for thyroid eye disease. It has two parts: one watches how long benefits last without treatment, and the other gives batoclimab to see if it helps more patients. The goal is to see if the drug can control eye bulg…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New gel shows promise for vitiligo, but study halted early
Disease control Stopped earlyThis study tested a gel called VYN201 for people with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the gel could reduce the size of these patches over 24 weeks. The trial involved 205 adults aged 18 to 75, but it was terminated…
Phase 2 • Sponsor: Vyne Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Monthly MS injection aims to halt disability progression
Disease control Stopped earlyThis study tested a long-acting form of glatiramer acetate (GA Depot) given as a monthly shot to people with primary progressive multiple sclerosis (PPMS). The goal was to see if it could safely slow down worsening disability. The trial was stopped early, but it involved 30 adult…
Phase 2 • Sponsor: Mapi Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hydroxychloroquine's effect on arteries in APS studied, but trial cut short
Disease control Stopped earlyThis study looked at whether hydroxychloroquine (Plaquenil) could improve artery function in people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. Researchers planned to give either hydroxychloroquine or a placebo to 25 participants and mea…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug telitacicept tested for MS Flare-Ups
Disease control Stopped earlyThis phase 2 trial tested telitacicept (RC18) in 8 people with relapsing-remitting multiple sclerosis. The drug aims to reduce relapses by targeting B cells. The study was terminated early, so we have limited data on safety and effectiveness.
Phase 2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Lupus flare prevention drug trial halted early
Disease control Stopped earlyThis study tested a drug called PRV-3279 to see if it could prevent lupus flares in people with active systemic lupus erythematosus (SLE). The trial included 28 adults with moderate to severe lupus who had improved after steroid treatment. The study was terminated early, so resul…
Phase 2 • Sponsor: Provention Bio, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Tiny MS drug safety study stopped early – no results yet
Disease control Stopped earlyThis was a very early Phase 1 study testing the safety of a drug called bryostatin in just 4 people with multiple sclerosis. Participants received multiple doses over 26 weeks. The study was terminated, meaning it stopped early, so we don't have clear results on whether the drug …
Phase 1 • Sponsor: Robert Fox • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
CBD-Hydroxychloroquine combo tested for arthritis pain – but trial ends early
Disease control Stopped earlyThis study tested a combination pill called IHL-675A, which contains cannabidiol (CBD) and hydroxychloroquine, in people with rheumatoid arthritis. The goal was to see if it safely reduces pain and improves daily function. The trial planned to enroll 128 volunteers but was termin…
Phase 2 • Sponsor: Incannex Healthcare Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug HZN-825 tested for rare scleroderma lung and skin damage
Disease control Stopped earlyThis trial tested an experimental drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage the lungs. Participants took either a low dose, a high dose, or a placebo daily for 52 weeks. …
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New shoulder implant tested for severe arthritis – but study halted early
Disease control Stopped earlyThis study looked at the TITAN Reverse Shoulder System, a device used to replace the shoulder joint in people with severe arthritis and a torn rotator cuff. The goal was to see if it relieves pain and improves movement. About 151 people were planned to take part, but the study wa…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to tame gluten reaction in celiac disease
Disease control Stopped earlyThis study tested an experimental drug called KAN-101 in people with celiac disease. The goal was to see if it could safely reduce the immune response to gluten. The trial included 128 participants and was split into phases to check safety and how the body processes the drug. How…
Phase 1/2 • Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for rare kidney disease? trial tests imlifidase
Disease control Stopped earlyThis study tested a new drug called imlifidase for people with severe Goodpasture disease, a rare condition where the immune system attacks the kidneys and lungs. The trial compared imlifidase plus standard care to standard care alone in 50 adults with poor kidney function. The g…
Phase 3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug shows promise for blistering skin disease in extended trial
Disease control Stopped earlyThis study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New tech approach aims to prevent repeat hospital stays for diabetes patients
Disease control Stopped earlyThis study tested whether a team-based approach using continuous glucose monitors could help adults with type 1 diabetes better control their blood sugar and avoid another hospital stay after a diabetic ketoacidosis (DKA) episode. Only 2 people enrolled before the study was stopp…
Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Melatonin trial for MS halted early – what we know
Disease control Stopped earlyThis study tested whether adding melatonin to the standard drug ocrelizumab could safely slow disability in people with progressive primary multiple sclerosis. The trial was terminated early, so results are limited. Participants were adults aged 18–65 with this type of MS.
Phase 1/2 • Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Lupus skin drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental oral drug called edecesertib (GS-5718) in 20 people with cutaneous lupus erythematosus, a condition where lupus affects the skin. The goal was to see if the drug could reduce skin disease activity and improve symptoms. However, the trial was term…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental drug tested for stubborn blood disorder – but trial cut short
Disease control Stopped earlyThis early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental CAR t therapy for severe muscle weakness hits early hurdle
Disease control Stopped earlyThis early trial tested an experimental drug called HN2301, a type of CAR T cell therapy made inside the body, for people with refractory myasthenia gravis — a condition causing severe muscle weakness that doesn't respond well to standard treatments. The study planned to enroll 9…
Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control Stopped earlyThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental drug for rare inflammatory disease shows early promise but trial cut short
Disease control Stopped earlyThis study tested elotuzumab, a drug used for multiple myeloma, in people with active IgG4-related disease (IgG4-RD), a rare condition causing inflammation and organ damage. The trial was small (only 8 participants) and was terminated early, so it is unclear if the drug is safe o…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Gut bacteria swap explored as MS treatment in early trial
Disease control Stopped earlyThis early-phase study tested whether a fecal transplant from a healthy donor could be safe and affect the immune system in people with relapsing-remitting multiple sclerosis. Only 5 participants were enrolled before the study was stopped. The goal was to see if changing gut bact…
Phase 1 • Sponsor: Jeffrey Gelfand • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control Stopped earlyThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Early-Stage lung blood pressure drug trial halted
Disease control Stopped earlyThis study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Lupus drug trial halted early: what we know
Disease control Stopped earlyThis study tested a weekly injection called telitacicept against a placebo in 91 people with moderate-to-severe lupus. The goal was to see if the drug could reduce disease activity and allow lower steroid doses. However, the trial was terminated early, so we have less information…
Phase 3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental drug HZN-825 tested for rare autoimmune lung complication
Disease control Stopped earlyThis trial tested the drug HZN-825 in 174 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that can scar the lungs. Participants took the drug twice daily for 52 weeks to see if it helped maintain lung function and to check for side effects. The study w…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Lupus kidney drug trial halted midway
Disease control Stopped earlyThis study tested a drug called zetomipzomib for people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could improve kidney function better than a placebo over 52 weeks. The trial was terminated early, so results are limited. Partic…
Phase 2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Promising drug for Post-Transplant blood issues falls short in early trial
Disease control Stopped earlyThis study tested a drug called fostamatinib to help people whose blood cell counts drop after a stem cell transplant. The goal was to see if the drug could raise red blood cells or platelets without needing transfusions. The trial was stopped early after enrolling only one perso…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug peresolimab tested for rheumatoid arthritis – study ends early
Disease control Stopped earlyThis study tested peresolimab, an experimental drug, in 491 adults with moderately-to-severely active rheumatoid arthritis who had not responded well to other treatments. The goal was to see if peresolimab could reduce joint pain and swelling better than a placebo. However, the s…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New MS drug trial for japanese patients shows promise but study stopped early
Disease control Stopped earlyThis study tested the drug natalizumab in 21 Japanese adults with relapsing-remitting multiple sclerosis (MS). The goal was to see if injections under the skin every 4 weeks could reduce new brain lesions over 24 weeks, and to check safety for up to 48 weeks. The study was termin…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental drug aims to restore platelets in Heparin-Triggered disorder
Disease control Stopped earlyThis study tested an experimental drug called VLX-1005 in people with a rare condition where the blood thinner heparin causes a dangerous drop in platelets (cells that help blood clot). Participants received either VLX-1005 or a placebo alongside standard care. The goal was to se…
Phase 2 • Sponsor: Veralox Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Smart device helps arthritis patients stay on track
Disease control Stopped earlyThis study looked at whether a smart injection device (Smartclic) helps rheumatoid arthritis patients take their etanercept medication as prescribed. Researchers tracked 60 patients in Colombia for 40 weeks, measuring how often they used the device and how their symptoms changed.…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
AI-Powered diabetes coach could replace some doctor visits
Disease control Stopped earlyThis study tested a software called DreaMed Advisor Pro that automatically analyzes blood sugar and insulin pump data to suggest insulin dose adjustments. About 100 people with type 1 diabetes (ages 6-30) were split into two groups: one received recommendations directly from the …
Sponsor: Rabin Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Promising drug for rare blood disorder trial halted early
Disease control Stopped earlyThis phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. Ho…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug iptacopan tested for rare blood disorders
Disease control Stopped earlyThis study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
MS drug trial halted after failing to lower nerve damage
Disease control Stopped earlyThis study tested an oral drug called SAR443820 in 174 adults with multiple sclerosis (MS) to see if it could lower a marker of nerve damage in the blood. The trial was stopped early because the drug did not meet its main goal of reducing that marker. Participants were followed f…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Knee implant study halted early: what we know
Disease control Stopped earlyThis study looked at how well the P.F.C. Sigma knee replacement implant works in people with severe knee arthritis. Researchers planned to follow 723 patients for at least 5 years after surgery, tracking pain, function, and any complications. However, the study was terminated ear…
Phase 4 • Sponsor: DePuy International • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can a smartphone app replace doctor visits for arthritis patients?
Disease control Stopped earlyThis study tested whether using a smartphone app and a hand grip device could help people with rheumatoid arthritis manage their condition with fewer in-person doctor visits. About 94 adults with active rheumatoid arthritis were randomly assigned to use the app or continue standa…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug for rare blood disorder tested for long-term safety
Disease control Stopped earlyThis study tested the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. Only 9 participants were enrolled, and the study was terminated early. The goal was to see if the drug is sa…
Phase 1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 16:38 UTC
-
Lupus drug combo tested in tiny trial – but study halted early
Disease control Stopped earlyThis phase 2 trial tested the drugs mycophenolate mofetil (CellCept) alone or with voclosporin in 12 people with lupus. The goal was to see if these treatments work better in certain patient groups. However, the study was terminated early, so the results are very limited.
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 15:22 UTC
-
Myasthenia gravis drug trial halted early – only 6 patients enrolled
Disease control Stopped earlyThis study tested tolebrutinib, an oral drug, in adults with moderate-to-severe generalized myasthenia gravis. The trial was a Phase 3, double-blind, placebo-controlled study that planned to enroll many participants but was terminated early with only 6 people enrolled. Because it…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 14:27 UTC
-
New automated insulin system tested in tiny trial
Disease control Stopped earlyThis study tested a system that automatically adjusts insulin delivery using a continuous glucose monitor, a smartphone app, and an insulin pump. It aimed to see if the system could help adults with type 1 diabetes spend more time with their blood sugar in a healthy range. Only o…
Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 26, 2026 12:39 UTC
-
Blood test may tame the tightrope walk of transplant drugs
Diagnosis Stopped earlyThis study tests whether a blood test called TruGraf can help doctors fine-tune immunosuppression medications in liver transplant recipients with autoimmune liver diseases like autoimmune hepatitis, primary sclerosing cholangitis, or primary biliary cirrhosis. The test measures g…
Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
AI reads eye photos to spot Diabetes-Related vision loss
Diagnosis Stopped earlyThis study tests whether an artificial intelligence program called NeoRetina can accurately detect diabetic retinopathy and diabetic macular edema from simple eye photographs. Researchers will compare the AI's analysis to standard exams by eye doctors. The goal is to see if this …
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Tears may replace spinal taps for MS diagnosis
Diagnosis Stopped earlyThis study tests whether a tear sample can diagnose primary progressive multiple sclerosis (MS) as accurately as a spinal tap. Currently, doctors need to collect spinal fluid to confirm this type of MS, which is invasive and uncomfortable. Researchers will compare proteins in tea…
Sponsor: Lille Catholic University • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis Stopped earlyThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis Stopped earlyThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC
-
Can High-Tech toothbrushes protect gums in scleroderma?
Symptom relief Stopped earlyThis trial tests whether using a sonic toothbrush and a water flosser improves gum health better than a standard manual toothbrush in people with systemic sclerosis, a rare disease that often affects the mouth. About 20 adults with the condition will be randomly assigned to one o…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can a home exercise program help Hispanics/Latinos with MS?
Symptom relief Stopped earlyThis study tested whether a 4-month exercise program done at home could help Hispanic/Latino adults with multiple sclerosis (MS) improve their physical function, manage symptoms, and feel better overall. Participants worked with coaches via video calls and compared results to a c…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Pain pill showdown: ultracet vs. voltaren for back inflammation
Symptom relief Stopped earlyThis study compared two pain medications—Ultracet (tramadol/acetaminophen) and Voltaren (diclofenac)—in people with ankylosing spondylitis who were already taking disease-modifying anti-rheumatic drugs (DMARDs). The goal was to see which one worked better for pain relief over 8 w…
Phase 4 • Sponsor: Johnson & Johnson Taiwan Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New injection targets psoriatic arthritis pain in small trial
Symptom relief Stopped earlyThis early-stage study tested the safety of an experimental drug called Allocetra, injected directly into the joint, for people with psoriatic arthritis. Only 5 participants were enrolled. The main goal was to check for side effects, with some initial data on pain relief. The stu…
Phase 1 • Sponsor: Enlivex Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Laser hope for scars and scleroderma fizzles in tiny trial
Symptom relief Stopped earlyThis study tested whether a special laser could improve scars and skin hardening from scleroderma. Only 6 people took part, and the study was stopped early. Researchers measured scar changes using a standard scale, but the small size and early termination mean we cannot draw firm…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Can hand exercises and electrical stimulation ease MS sensory problems?
Symptom relief Stopped earlyThis study tested a rehabilitation program for hand sensitivity problems in people with multiple sclerosis. The program used TENS (a mild electrical stimulation device) and hand exercises to improve the ability to feel and recognize objects. The goal was to improve quality of lif…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
MS fatigue drug study halted early
Symptom relief Stopped earlyThis study aimed to see if the drug ozanimod could help reduce fatigue in people with multiple sclerosis (MS). Researchers planned to follow 26 adults with MS for three months, measuring fatigue using special questionnaires and brain scans. The study was terminated early, so resu…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
New eye drop shows promise for Sjögren's dry eye relief
Symptom relief Stopped earlyThis early-phase trial tested a new eye drop called rhPRG4 in 8 people with Sjögren's syndrome-related dry eye. Participants received either the active drop or a placebo, then switched after 90 minutes. The study measured eye dryness and safety over a single day. Because the tria…
Phase 1/2 • Sponsor: Lubris Bio Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
RA patients paired with buddies to boost Well-Being
Symptom relief Stopped earlyThis study tested a program where people with rheumatoid arthritis (RA) were paired with a trained peer supporter for up to 6 months. The goal was to see if sharing experiences and support could improve daily function, medication adherence, and symptoms like pain and fatigue. The…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Contact lens coating replenisher tested for rare eye conditions
Symptom relief Stopped earlyThis study tested a monthly solution called Tangible Boost that is meant to restore a special coating on contact lenses. The goal was to see if it could improve comfort and vision in people with severe dry eye from Stevens-Johnson syndrome, Sjogren's syndrome, or graft-versus-hos…
Sponsor: Tangible Science • Aim: Symptom relief
Last updated Jun 26, 2026 18:06 UTC
-
Abandoned trial: only 2 patients tested for stomach relief in muscle disease
Symptom relief Stopped earlyThis small, early-stage trial tested whether adding ondansetron (an anti-nausea drug) to pyridostigmine (a standard myasthenia gravis treatment) could reduce stomach side effects like nausea, vomiting, or diarrhea. Only 2 people with anti-AchR positive myasthenia gravis were enro…
Phase 2 • Sponsor: DAS-MG, Inc • Aim: Symptom relief
Last updated Jun 26, 2026 15:47 UTC
-
Brain fatigue after thyroid disease: immune system may be to blame
Knowledge-focused Stopped earlyThis study investigates why some people with Graves' disease continue to feel mentally fatigued even after their thyroid levels return to normal. Researchers will compare blood and spinal fluid from 180 participants—60 with mental fatigue, 60 without, and 60 healthy controls—to f…
Sponsor: Vastra Gotaland Region • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can pressurized oxygen tame blood sugar spikes?
Knowledge-focused Stopped earlyThis study asks whether a single session of hyperbaric oxygen therapy (HBOT) can lower blood sugar or change glucagon levels in people with type 1 or type 2 diabetes. Participants will undergo one HBOT session and one control session (sitting in a room at normal pressure), while …
Sponsor: Legacy Health System • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Hidden toll of diabetes caregiving revealed in new study
Knowledge-focused Stopped earlyThis study looks at how caring for a child recently diagnosed with type 1 diabetes affects caregivers' work, daily life, and well-being. About 100 Canadian caregivers will fill out online questionnaires about their productivity, healthcare use, and quality of life. No treatment i…
Sponsor: PeriPharm • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Biopsy tolerance study ends early – what we know
Knowledge-focused Stopped earlyThis study aimed to understand how well patients tolerate biopsies for autoimmune diseases and whether they feel properly informed. It planned to enroll 505 people but was terminated early. The results may help improve patient experience with these common procedures.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New MRI scans reveal hidden brain changes after first MS symptoms
Knowledge-focused Stopped earlyThis study used a special MRI technique to look at tiny brain changes in people who recently had a first episode of symptoms that could lead to multiple sclerosis (MS). Researchers compared 84 participants (patients and healthy controls) to see if early memory problems are linked…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
Knowledge-focused Stopped earlyThis study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people wi…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Could a common virus trigger thyroid troubles?
Knowledge-focused Stopped earlyThis study investigated whether polyomaviruses (a type of common virus) are found more often in people with autoimmune thyroiditis or goiters. Researchers compared virus presence in blood, urine, and thyroid tissue from 49 patients undergoing thyroid surgery. The goal was to see …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Yeast study in rare autoimmune disease terminated early
Knowledge-focused Stopped earlyThis study aimed to compare the types of Candida yeast found in patients with two forms of autoimmune polyendocrinopathy, a rare condition where the immune system attacks multiple glands. Researchers planned to collect samples from the mouth and urine of 7 participants to see how…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Painkiller showdown: which is safer for the heart?
Knowledge-focused Stopped earlyThis study looked at how two common pain relievers—celecoxib (a Coxib) and naproxen (an NSAID)—affect blood clotting in people with rheumatoid arthritis who also have heart disease or are at high risk for it. All participants took low-dose aspirin daily. The goal was to see if on…
Phase 4 • Sponsor: Platelet and Thrombosis Research, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Blood test may predict dangerous MS rebound after stopping popular drug
Knowledge-focused Stopped earlyThis small, early-terminated study explored whether measuring certain receptors on immune cells could predict disease activity and rebound risk in multiple sclerosis patients taking or stopping ozanimod. Researchers analyzed blood samples from 23 adults with relapsing-remitting M…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Microscope inside the lungs reveals hidden damage in two diseases
Knowledge-focused Stopped earlyThis study used a special microscope on the tip of a thin tube (bronchoscope) to look at the smallest blood vessels in the lungs of people with scleroderma or emphysema. The goal was to see how these vessels change in each disease. Only 9 patients were enrolled before the study w…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
What sets off MS Flare-Ups? scientists investigate stress and hormones
Knowledge-focused Stopped earlyThis study looked at how stress, hormonal cycles, illness, and missed medications might affect when symptoms appear or get worse in women with relapsing-remitting multiple sclerosis (RR-MS). Researchers planned to track 80 women over time, recording daily symptom changes. The stu…
Sponsor: University of Louisville • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Gut microbiome study in kids with autoimmune diseases ends early
Knowledge-focused Stopped earlyThis study aimed to compare the gut bacteria of children newly diagnosed with juvenile idiopathic arthritis, type 1 diabetes, or inflammatory bowel disease with those of their healthy siblings. Researchers wanted to see if differences in gut microbes and diet could explain why so…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Arthritis drugs and COVID: study probes immune response
Knowledge-focused Stopped earlyThis study looked at how immunosuppressive medications used for rheumatoid arthritis and spondyloarthritis affect the body's ability to fight COVID-19. Researchers measured viral load and immune responses in 150 patients and their infected family members. The goal was to understa…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
MRI scans aim to predict tysabri success in MS patients
Knowledge-focused Stopped earlyThis study looked at whether special MRI scans can detect early brain changes in people with multiple sclerosis who are starting treatment with Tysabri. Researchers planned to follow 70 patients for two years, comparing MRI images before and after treatment. The goal was to find …
Phase 4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Small study tests blood sugar targets to prevent lows during exercise in type 1 diabetes
Knowledge-focused Stopped earlyThis study looked at people with type 1 diabetes who use do-it-yourself automated insulin delivery (DIY-AID) systems. Researchers wanted to find the best blood glucose target to set 60 minutes before moderate aerobic exercise (like cycling) to keep blood sugar stable and avoid da…
Sponsor: Institut de Recherches Cliniques de Montreal • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can your personality change your diabetes genes?
Knowledge-focused Stopped earlyThis study looked at whether people with type 1 or type 2 diabetes who have a 'Type A' (impatient, proactive) or 'Type B' (calm, slow) personality show different genetic markers linked to inflammation and stress. Researchers planned to collect blood samples and have participants …
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Lupus and COVID vaccines: immune response under the microscope
Knowledge-focused Stopped earlyThis study aimed to understand how the COVID-19 vaccine impacts the immune system in people with lupus, a chronic autoimmune disease. Researchers planned to enroll lupus patients to measure their immune response to the vaccine and see if lupus disease activity or treatments affec…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New hip implant put to the test: will it stay put?
Knowledge-focused Stopped earlyThis study looked at a specific hip implant shell (the Pinnacle Acetabular Shell) used in total hip replacement. Researchers wanted to see how much the implant moved (migrated) over two years using a special X-ray technique called RSA. They also tracked how patients felt and func…
Sponsor: DePuy Orthopaedics • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Wearable device aims to track MS progression from home
Knowledge-focused Stopped earlyThis study tested a wearable device called Syde® in 86 people with multiple sclerosis. Participants wore the device for one month every six months over two years. The goal was to see if the device's activity data matches standard clinic tests like walking speed and disability sco…
Sponsor: SYSNAV • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Tablet teaching for diabetes: a High-Tech hope for new patients?
Knowledge-focused Stopped earlyThis study tested whether using a bedside tablet with interactive education modules helps people newly diagnosed with type 1 diabetes learn more than standard paper-based materials. The trial planned to enroll 28 patients but was terminated early. Researchers measured diabetes kn…
Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Elderly arthritis study reveals hidden health risks
Knowledge-focused Stopped earlyThis study aimed to understand how age influences serious health issues like infections, cancer, heart disease, and bone fractures in people with rheumatoid arthritis. Researchers compared patients over 65 with younger adults (18-50) who had the same disease. The study was stoppe…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Sjögren's dry eye study probes corneal nerve damage
Knowledge-focused Stopped earlyThis study aimed to find out how many people with Sjögren's dry eye have reduced feeling in their cornea (the clear front part of the eye). Researchers measured corneal sensitivity, tear production, and pain in 103 adults with confirmed Sjögren's syndrome and dry eye. The study w…
Sponsor: Dompé Farmaceutici S.p.A • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Can a fitness watch help kids with diabetes get moving?
Knowledge-focused Stopped earlyThis study looked at whether wearing a Garmin Vivosmart activity tracker could increase physical activity and improve diabetes control in children and young adults (ages 8-21) with Type 1 Diabetes. Participants wore the tracker for a year and completed surveys about their diabete…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Lab study explores how JAK inhibitors affect immune cells in arthritis
Knowledge-focused Stopped earlyThis study looked at how JAK-STAT inhibitors, a type of drug used for rheumatoid arthritis, affect certain immune cells called regulatory B cells. Researchers analyzed blood samples from 27 patients to see if these drugs could boost anti-inflammatory functions. The study was term…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Scientists probe immune cells in arthritic joints for clues
Knowledge-focused Stopped earlyThis pilot study analyzed special immune cells called regulatory T cells (Tregs) in the joint fluid of 19 people with rheumatoid arthritis during a flare-up. Researchers compared these cells to Tregs in the blood to understand how they behave in inflamed joints. No treatment was …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Tiny study probes hidden cause of foot pain in arthritis
Knowledge-focused Stopped earlyThis study looked at whether a condition called intermetatarsal bursitis (inflammation between foot bones) causes pain in people with rheumatoid arthritis. Researchers used MRI and ultrasound to examine the feet of 3 participants and tested steroid injections. The study was termi…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Study on arthritis and diabetes link halted early
Knowledge-focused Stopped earlyThis study looked at whether people with both rheumatoid arthritis and type 2 diabetes have a harder time controlling their diabetes than those with osteoarthritis and diabetes. Researchers planned to follow 176 adults to see how quickly they needed new diabetes treatments. Howev…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:07 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused Stopped earlyThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
Can two old drugs stop a dangerous diabetes complication?
Knowledge-focused Stopped earlyThis study tested whether two medications, naloxone (a nasal spray) and diazoxide (an oral pill), could prevent the body from losing its ability to sense low blood sugar—a condition called hypoglycemia unawareness. Only 4 healthy volunteers were enrolled before the trial was stop…
Phase 4 • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:35 UTC
-
Tiny study on drug monitoring in scleroderma ends early
Knowledge-focused Stopped earlyThis study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was termina…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:32 UTC